BMS demonstrates superior efficac
A systematic review and meta-analysis of randomised clinical trials (RCTs) underscores the superior efficacy of bariatric and metabolic surgery (BMS) over non-surgical treatments
Revita prevent weight regain
Fractyl Health has announced positive early data from the open-label REVEAL-1 cohort of its ongoing REMAIN-1 pivotal study. The results suggest that Revita, the company’s novel approach to targeting gut dysfunction, a root cause of obesity
BariPredict: Class II obesity
Outcomes from the BariPredict cohort have found that 65.8% prevalence of persons at risk of an eating disorder (ED) – opting for, but not yet undergone, bariatric surgery – was higher than expected and at-risk patient profile is defined by class II obesity, younger age and concurrent depression, according to researchers from Kuwait.